• Explore /
  • Poster
  • / PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.

PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.

Abstract Poster

Authors

null

Arun Azad

Peter MacCallum Cancer Centre, Melbourne, Australia

Arun Azad , Mark Voskoboynik , Anthony M. Joshua , Andrew James Weickhardt , Peter Sankey , Simon Pacey , Elisabeth I. Heath , Laurence Krieger , Lisa Horvath , Patrick Glen Pilié , Lynsey Womersley , Spiros Linardopoulos , Ganesh Moorthy , TJ Zhou , Jessica Brown , Bruno de Paula , Edit Lukacs , Andrew Hudson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05367440

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 123)

DOI

10.1200/JCO.2024.42.4_suppl.123

Abstract #

123

Poster Bd #

E16

Abstract Disclosures

Similar Posters

First Author: Arun Azad

First Author: Evan Y. Yu

Poster

2023 ASCO Quality Care Symposium

Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.

Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.

First Author: Nicholas Moffett

First Author: Arpit Rao